Dave Muoio
The Stasis system tracks six vital signs, and so far has largely been deployed in India.
A frequent partner of biopharmas and the FDA, it has raised $94 million from investors since its commercial launch in 2015.
The raise reportedly brings the company's valuation into unicorn territory.
The deal joins each company's voice sample datasets to improve R&D, and helps Sonde collect more data across platforms.
Under the banner of the Consumer Technology Association, the companies hope that clear standards will improve digital therapeutics adoption and implementation.
The consumer genomics company's existing offering, called AncestryHealth, sold clinician-ordered tests that were not cleared or approved by the FDA.
The data-driven blood glucose monitor system-maker will use the money to push into new areas of disease management, such as cardiology, oncology and women's health.
Also: Klara closes $15 million for digital patient engagement; Trellus Health collects $5 million seed funding and announces exclusive commercialization deal.
Also: Centauri Health Solutions acquires HCFS; UCSF researchers detail smartphone PPG-based diabetes detection.
The patient-facing EASE app is HIPAA compliant, and does not save any texts, photos or videos to the recipient's device.